var data={"title":"Griseofulvin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Griseofulvin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6285?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=griseofulvin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Griseofulvin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=griseofulvin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Griseofulvin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177520\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Grifulvin V [DSC];</li>\n      <li>Gris-PEG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177558\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177525\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatophyte infections:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Microsize:</i></b> 500 mg/day in single or divided doses; for more widespread lesions initial doses of 750 to 1,000 mg/day in single or divided doses may be needed; may decrease gradually to 500 mg/day or less if patient responds to higher dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Ultramicrosize:</b></i> 375 mg daily in single or divided doses; doses up to 750 mg/day in divided doses have been used for infections more difficult to eradicate such as tinea unguium and tinea pedis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Duration of therapy depends on the site of infection:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea corporis: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea cruris: Duration not specified in manufacturer&rsquo;s labeling; in pediatric patients 6 weeks has been recommended (<i>Red Book</i>, 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea capitis: 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea pedis: 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea unguium: 4 to 6 months or longer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991858\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989154\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in hepatic failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177541\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=griseofulvin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Griseofulvin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatophyte infections:</b> Children &gt;2 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Microsize: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Dosage should be individualized; 10 mg/kg/day in a single or divided doses (maximum daily dose: 500 mg/day) <b>or</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13.6 to 22.7 kg: 125 to 250 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;22.7 kg: 250 to 500 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 10 to 20 mg/kg/day in single or 2 divided doses (maximum: 1,000 mg/day) (<i>Red Book</i> [AAP 2015]); <b>Note:</b> Tinea capitis: 20 to 25 mg/kg/day has been recommended (Ali 2007; Lipozenic 2002; Sethi 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Ultramicrosize:</i></b> 5 to 15 mg/kg/day in single dose or 2 divided doses (maximum dose/day: 750 mg/day) (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Duration of therapy depends on the site of infection: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea corporis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: 6 weeks (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea cruris: 6 weeks (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea capitis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: Children: 6 to 12 weeks; use up to 16 weeks may be required (AAP <i>Red Book</i> recommends continuing treatment for 6 weeks or more and 2 weeks after clinical resolution of symptoms) (<i>Red Book</i> [AAP 2015]; Ali 2007; Lipozenic 2002; Sethi 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea pedis: 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea unguium: 4 to 6 months or longer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112851\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112852\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">All patients: Use is contraindicated in hepatic failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177526\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177502\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (118 mL [DSC], 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Grifulvin V: 500 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gris-PEG: 125 mg, 250 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177487\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123828\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Microsized formulations: Suspensions, Grifulvin V tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ultramicrosize formulation: Gris-PEG tablets</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177505\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with a fatty meal to increase absorption (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gris-PEG tablets: May be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and swallowed immediately without chewing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Shake well before use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177503\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatophyte infections:</b> Treatment of the following dermatophyte infections of the skin, hair, and nails not adequately treated by topical therapy: Tinea corporis, tinea pedis, tinea cruris, tinea barbae, tinea capitis, tinea unguium (onychomycosis) when caused by one or more of the following species of fungi: <i>Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis, Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum,</i> and <i>Epidermophyton floccosum</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Use for the prophylaxis of fungal infections has not been established; not effective for the treatment of tinea versicolor. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177494\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, dizziness, fatigue, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction (erythema multiforme-like drug reaction), skin photosensitivity, skin rash (most common), urticaria (most common)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, epigastric distress, gastrointestinal hemorrhage, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Granulocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, increased serum bilirubin, increased serum transaminases, leukopenia, lupus-like syndrome, paresthesia, proteinuria, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177508\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to griseofulvin or any component of the formulation; hepatic failure; porphyria; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177491\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Leukopenia has been reported (rare); discontinue therapy if granulocytopenia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: May cause jaundice and elevated liver function tests or bilirubin (may be serious or even fatal); monitor hepatic function and discontinue therapy if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Hypersensitivity cross reaction between penicillins and griseofulvin is possible, however, known penicillin-sensitive patients have been treated successfully without complications. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: Avoid exposure to intense sunlight to prevent photosensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) have been reported (may be serious or even fatal); discontinue use if severe skin reactions occur. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lupus erythematosus: Development of lupus erythematosus, lupus-like syndromes or exacerbation of existing lupus erythematosus has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use for the prophylaxis of fungal infections has not been established; not effective for the treatment of tinea versicolor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177554\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177496\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8502&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Griseofulvin.<b> Exceptions: </b>Methohexital; Thiopental.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Griseofulvin may enhance the adverse/toxic effect of Carbocisteine. Specifically, griseofulvin may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Griseofulvin may increase the metabolism of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Griseofulvin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Griseofulvin may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Griseofulvin may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177516\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Concomitant use will cause a &quot;disulfiram&quot;-type reaction consisting of tachycardia, flushing, headache, nausea, and in some patients, vomiting and chest and/or abdominal pain. Management: Avoid ethanol consumption during therapy; if ethanol is consumed, monitor patients for signs of reaction. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Griseofulvin concentrations may be increased if taken with food, especially with high-fat meals. Management: Take with a fatty meal (peanuts or ice cream) to increase absorption, or with food or milk to avoid GI upset.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20503046\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4293494\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have been observed in animal reproduction studies. Griseofulvin crosses the placenta (Pacifici, 2006). Because adverse events have also been observed in humans (two cases of conjoined twins), use during pregnancy is contraindicated. Effective contraception should be used during therapy and for 1 month after therapy is discontinued in women of reproductive potential.  Men should avoid fathering a child for at least 6 months after therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265843\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if griseofulvin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177500\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematopoietic function tests especially with long-term use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177490\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits fungal cell mitosis at metaphase; binds to human keratin making it resistant to fungal invasion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177507\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable (27% to 72% of an oral dose); enhanced by ingestion of a fatty meal (GI absorption of ultramicrosize is ~1.5 times that of microsize); absorbed from the duodenum</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Deposited in the keratin layer of skin, hair, and nails; concentrates in liver, fat, and skeletal muscles; V<sub>d</sub>: ~1.5  L (Vozeh 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 9 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1% as unchanged drug); feces (~33%); perspiration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177510\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Griseofulvin Microsize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (120 mL): $78.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gris-PEG Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $620.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $791.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Griseofulvin Microsize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $850.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Griseofulvin Ultramicrosize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $478.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $611.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177511\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afuvin (BD);</li>\n      <li>Asfulvin (LK);</li>\n      <li>Biogrisin (PL);</li>\n      <li>Delmofulvina (IT);</li>\n      <li>Fulcin (BR, EC, FI, IT, NO, PT, QA);</li>\n      <li>Fulcin Forte (MX);</li>\n      <li>Fulcin S (DE);</li>\n      <li>Fulcinex (BD);</li>\n      <li>Fulsovin (GB);</li>\n      <li>Fulvin G (BD);</li>\n      <li>Fungistop (ID);</li>\n      <li>Fungivin (NO, PK);</li>\n      <li>Fusovin (TH);</li>\n      <li>Gricin (CZ, DE, HU, PL);</li>\n      <li>Grifulin Forte (IL);</li>\n      <li>Grifulvin (TH);</li>\n      <li>Grisefuline (FR);</li>\n      <li>Grisen (TW);</li>\n      <li>Grisenova (GR);</li>\n      <li>griseo von ct (DE);</li>\n      <li>Griseofil (LK);</li>\n      <li>Griseofulvin (IE, PL);</li>\n      <li>Griseofulvin Leo (LU);</li>\n      <li>Griseofulvin Prafa (ID);</li>\n      <li>Griseofulvina (IT);</li>\n      <li>Griseomed (AT);</li>\n      <li>Griseovin (EG);</li>\n      <li>Griseovine (VN);</li>\n      <li>Grisflavin (TH);</li>\n      <li>Grisfulvin V (PH);</li>\n      <li>Grisol (CH);</li>\n      <li>Grisomicon (PT);</li>\n      <li>Grisoral (IN);</li>\n      <li>Grisovin (AE, AT, AU, BH, CO, CR, CY, CZ, DO, EG, GT, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, PT, QA, SA, SV, SY, VE, YE);</li>\n      <li>Grisovin F.P. (LK);</li>\n      <li>Grisovin-FP (AR, PH, UY);</li>\n      <li>Grisovina FP (IT);</li>\n      <li>Grisuven (HK);</li>\n      <li>Grisuvin (MY);</li>\n      <li>Grivin (MY, TH);</li>\n      <li>Grivin Forte (ID);</li>\n      <li>Japcin (BD);</li>\n      <li>Krisovin (MY, SG);</li>\n      <li>Likuden (DE);</li>\n      <li>Microcidal (ZA);</li>\n      <li>Pongyl V (KR);</li>\n      <li>Ponzyr V (KR);</li>\n      <li>Rexavin (ID);</li>\n      <li>Trivanex (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ali S, Graham TA, and Forgie SE, &quot;The Assessment and Management of Tinea Capitis in Children,&quot; <i>Pediatr Emerg Care</i>, 2007, 23(9):662-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/17876261/pubmed\" target=\"_blank\" id=\"17876261\">17876261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Araujo OE, Flowers FP, and King MM, &quot;Griseofulvin: A New Look at an Old Drug,&quot; <i>Ann Pharmacother</i>, 1990, 24(9):851-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/2260345/pubmed\" target=\"_blank\" id=\"2260345\">2260345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleece D, Gaughan JP, and Aronoff SC, &ldquo;Griseofulvin Versus Terbinafine in the Treatment of Tinea Capitis: A Meta-Analysis of Randomized, Clinical Trials,&rdquo; <i>Pediatrics</i>, 2004, 114(5):1312-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/15520113/pubmed\" target=\"_blank\" id=\"15520113\">15520113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuller LC, Smith CH, Cerio R, et al, &ldquo;A Randomized Comparison of 4 Weeks of Terbinafine vs 8 Weeks of Griseofulvin for the Treatment of Tinea Capitis,&rdquo; <i>Br J Dermatol</i>, 2001, 144(2):321-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/11251566/pubmed\" target=\"_blank\" id=\"11251566\">11251566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ginsburg CM, McCracken GH Jr, Petruska M, et al, &ldquo;Effect of Feeding on Bioavailability of Griseofulvin in Children,&rdquo; <i>J Pediatr</i>, 1983, 102(2):309-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/6822943/pubmed\" target=\"_blank\" id=\"6822943\">6822943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griseofulvin oral suspension [prescribing information]. Miami, FL: Cipla USA Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gris-PEG [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kawabe Y, Mizuno N, Miwa N, et al, &ldquo;Photosensitivity Induced by Griseofulvin,&rdquo; <i>Photodermatol</i>, 1988, 5(6):272-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/3249685/pubmed\" target=\"_blank\" id=\"3249685\">3249685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecky BR, &ldquo;Griseofulvin-Induced Neuropathy,&rdquo; <i>Lancet</i>, 1990, 335(8683):230-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis RE, &quot;Current Concepts in Antifungal Pharmacology,&quot; <i>Mayo Clin Proc </i>, 2011, 86(8):805-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/21803962/pubmed\" target=\"_blank\" id=\"21803962\">21803962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipozencic J, Skerlev M, Orofino-Costa R, et al, &ldquo;A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study of Oral Terbinafine and Open-Label, High-Dose Griseofulvin in Children With Tinea Capitis due to <i>Microsporum</i> Species,&rdquo; <i>Br J Dermatol</i>, 2002, 146(5):816-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/12000378/pubmed\" target=\"_blank\" id=\"12000378\">12000378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mion G, Verdon R, Le Gulluche Y, et al, &ldquo;Fatal Toxic Epidermal Necrolysis After Griseofulvin,&rdquo; <i>Lancet</i>, 1989, 2(8675):1331.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacifici GM, &quot;Placental Transfer of Antibiotics Administered to the Mother: A Review,&quot; <i>Int J Clin Pharmacol Ther</i>, 2006, 44(2):57-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/16502764/pubmed\" target=\"_blank\" id=\"16502764\">16502764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pomeranz AJ and Sabnis SS, &ldquo;Tinea Capitis: Epidemiology, Diagnosis and Management Strategies,&rdquo; <i>Paediatr Drugs</i>, 2002, 4(12):779-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/12431130/pubmed\" target=\"_blank\" id=\"12431130\">12431130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book&reg;: 2015 Report of the Committee on Infectious Diseases</i>, 30th ed, Kimberlin DW, ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015, 712-714; 832t.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sethi A and Antaya R, &quot;Systemic Antifungal Therapy for Cutaneous Infections in Children,&quot; <i>Pediatr Infect Dis J</i>, 2006, 25(7):643-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/16804437/pubmed\" target=\"_blank\" id=\"16804437\">16804437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sladden MJ and Johnston GA, &ldquo;Common Skin Infections in Children,&rdquo; <i>BMJ</i>, 2004, 329(7457):95-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/15242915/pubmed\" target=\"_blank\" id=\"15242915\">15242915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trepanier EF and Amsden GW, &ldquo;Current Issues in Onchomycosis,&rdquo; <i>Ann Pharmacother</i>, 1998, 32(2):204-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/9496407/pubmed\" target=\"_blank\" id=\"9496407\">9496407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo; <i>Clin Pharmacokinetics</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang DJ and Rankin GO, &ldquo;Nephrotoxicity of Antifungal Agents,&rdquo; <i>Adverse Drug React Acute Poisoning Rev</i>, 1985, 4(1):37-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-drug-information/abstract-text/3890481/pubmed\" target=\"_blank\" id=\"3890481\">3890481</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8502 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F177520\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F177558\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177525\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991858\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989154\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F177541\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112851\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112852\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F177526\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177502\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F177487\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22123828\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F177505\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F177503\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177494\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177508\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177491\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F177554\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177496\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F177516\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F20503046\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4293494\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16265843\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F177500\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177490\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F177507\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F177510\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177511\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8502|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=griseofulvin-patient-drug-information\" class=\"drug drug_patient\">Griseofulvin: Patient drug information</a></li><li><a href=\"topic.htm?path=griseofulvin-pediatric-drug-information\" class=\"drug drug_pediatric\">Griseofulvin: Pediatric drug information</a></li></ul></div></div>","javascript":null}